Moderna, Inc. (BVMF:M1RN34)

Brazil flag Brazil · Delayed Price · Currency is BRL
6.41
-0.04 (-0.62%)
At close: Dec 2, 2025
-52.45%
Market Cap52.18B
Revenue (ttm)11.90B
Net Income (ttm)-16.61B
Shares Outn/a
EPS (ttm)-42.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume29,984
Average Volume106,184
Open6.50
Previous Close6.45
Day's Range6.40 - 6.57
52-Week Range6.02 - 14.89
Beta1.11
RSI49.14
Earnings DateNov 6, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Brazil Stock Exchange
Ticker Symbol M1RN34
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.